This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
GlycoMimetics, Inc. [GLYC], a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role, will visit the NASDAQ MarketSite in Times Square. GLYC initial public offering on January 10, 2014 was the first of the year on all U.S. exchanges.
In honor of the occasion,
Rachel King, Chief Executive Officer will ring the Closing Bell.
NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
Friday, April 11, 2014 – 3:45 p.m. to 4:00 p.m. ET
GlycoMimetics, Inc. Contact:
Brian Hahn (240) 243-1207
Christine Barna (646) 441-5310
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For photos from ceremonies and events visit our Instagram Page:
For news tweets, please visit our Twitter page at:
For exciting viral content and ceremony photos visit Tumblr Page:
A webcast of the NASDAQ Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About GlycoMimetics, Inc. [GLYC]:
GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.